{"slug":"outcomes","tag":"outcomes","variants":["outcomes"],"description":"No description yet","count":5,"kinds":{"person":3,"bottleneck":1,"idea":1},"related":[{"slug":"methods","tag":"methods","shared":2},{"slug":"open-problem","tag":"open-problem","shared":2},{"slug":"rejuvenation","tag":"rejuvenation","shared":2},{"slug":"supportive-care","tag":"supportive-care","shared":2},{"slug":"survivorship","tag":"survivorship","shared":2},{"slug":"canada","tag":"canada","shared":1},{"slug":"lymphoma","tag":"lymphoma","shared":1},{"slug":"palliative-care","tag":"palliative-care","shared":1},{"slug":"patient-reported-outcomes","tag":"patient-reported-outcomes","shared":1}],"records":[{"id":"laurie-sehn","kind":"person","name":"Laurie H. Sehn","route":"/people/laurie-sehn/","tldr":"Lymphoma specialist who wrote the definitive DLBCL review and helped establish polatuzumab and other new agents."},{"id":"jennifer-temel","kind":"person","name":"Jennifer S. Temel","route":"/people/jennifer-temel/","tldr":"Showed that early palliative care helps lung cancer patients live better and longer, changing oncology guidelines worldwide."},{"id":"ethan-basch","kind":"person","name":"Ethan Basch","route":"/people/ethan-basch/","tldr":"Proved that letting patients report symptoms electronically during chemotherapy improves quality of life and survival."},{"id":"rejuv-agenda-no-agreed-outcome-measures","kind":"bottleneck","name":"The field cannot pool its own studies, because it has not agreed what to measure","route":"/bottlenecks/rejuv-agenda-no-agreed-outcome-measures/","tldr":"On subject after subject here, the studies exist and cannot be combined, because each used a different definition, a different questionnaire or a different threshold. A prevalence that ranges from 0 to 84 per cent is a measurement problem, not a biological one."},{"id":"idea-rejuv-core-outcome-set-for-late-effects","kind":"idea","name":"Agree what to measure, so the next systematic review can pool rather than narrate","route":"/ideas/idea-rejuv-core-outcome-set-for-late-effects/","tldr":"A reported prevalence of 0 to 84 per cent for the same late effect is a measurement failure. Core outcome sets are cheap, need no new biology, and would unlock the studies the field has already paid for."}]}